ATE363468T1 - Ningalin b analoga geeignet zur aufhebung der mehrfachmedikamentenresistenz - Google Patents

Ningalin b analoga geeignet zur aufhebung der mehrfachmedikamentenresistenz

Info

Publication number
ATE363468T1
ATE363468T1 AT01913273T AT01913273T ATE363468T1 AT E363468 T1 ATE363468 T1 AT E363468T1 AT 01913273 T AT01913273 T AT 01913273T AT 01913273 T AT01913273 T AT 01913273T AT E363468 T1 ATE363468 T1 AT E363468T1
Authority
AT
Austria
Prior art keywords
ningalin
pyrrole
drug resistance
multiple drug
removing multiple
Prior art date
Application number
AT01913273T
Other languages
English (en)
Inventor
Dale Boger
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE363468T1 publication Critical patent/ATE363468T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
AT01913273T 2000-03-01 2001-03-01 Ningalin b analoga geeignet zur aufhebung der mehrfachmedikamentenresistenz ATE363468T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18610600P 2000-03-01 2000-03-01

Publications (1)

Publication Number Publication Date
ATE363468T1 true ATE363468T1 (de) 2007-06-15

Family

ID=22683673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01913273T ATE363468T1 (de) 2000-03-01 2001-03-01 Ningalin b analoga geeignet zur aufhebung der mehrfachmedikamentenresistenz

Country Status (8)

Country Link
US (1) US7250409B2 (de)
EP (1) EP1263723B1 (de)
JP (1) JP2003525271A (de)
AT (1) ATE363468T1 (de)
AU (1) AU2001241952A1 (de)
CA (1) CA2401673A1 (de)
DE (1) DE60128661D1 (de)
WO (1) WO2001064635A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026496A2 (en) * 2004-08-27 2006-03-09 Memorial Sloan-Kettering Cancer Center Immunosuppressive ningalin compounds
JP4982842B2 (ja) * 2006-02-08 2012-07-25 国立大学法人 長崎大学 ラメラリンサルフェートおよび関連化合物の製造方法
EP2809662B1 (de) * 2012-02-01 2018-07-04 City of Hope Ribonucleotidreduktaseinhibitoren und verfahren zur verwendung
WO2015013581A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852033A (en) * 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
AUPO656597A0 (en) * 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
AUPP433398A0 (en) * 1998-06-25 1998-07-16 Australian National University, The Compounds and processes

Also Published As

Publication number Publication date
AU2001241952A1 (en) 2001-09-12
US7250409B2 (en) 2007-07-31
WO2001064635A1 (en) 2001-09-07
EP1263723A1 (de) 2002-12-11
CA2401673A1 (en) 2001-09-07
EP1263723B1 (de) 2007-05-30
DE60128661D1 (de) 2007-07-12
US20030220320A1 (en) 2003-11-27
JP2003525271A (ja) 2003-08-26
EP1263723A4 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
Thomas et al. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity
DE69118680D1 (de) Russ der einen verbesserten widerstand gegen den laufflächenverschleiss und eine geringere hysterese verleiht und prozess für dessen herstellung
CA2147606A1 (en) Stable Extended Release Oral Dosage Composition
MXPA03011527A (es) Champus con alcohol behenilo.
DE60124587D1 (de) 2-butyl-3-(4-3(dibutylamino)propoxyü benzoyl)-5-nitrobenzofuran-hydrochlorid und dessen herstellung
EP1344780A4 (de) Glucopyranosyloxybenzylbenzolderivate, medizinische zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte für deren herstellung
IT1271462B (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
EP1762236A3 (de) Formulierungen von alpha-adrenergen Rezeptor-Antagonisten und ihre Anwendungen
ATE206119T1 (de) Thiacyclische piperidinylderivate
DE69112837D1 (de) Wasserlösliche pentacyclische triterpen-mischung sowie deren herstellung.
ATE252542T1 (de) Benzolderivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen,die diese enthalten
FR2733154B1 (fr) Composition superabsorbante destinee a la realisation d'article d'hygiene du type linges, couches, changes ne developpant pas d'odeurs incommodantes
HUP9903104A2 (hu) Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása, alkalmazásuk és glicinantagonistaként ezeket tartalmazó gyógyszerkészítmények
ATE363468T1 (de) Ningalin b analoga geeignet zur aufhebung der mehrfachmedikamentenresistenz
ATE103918T1 (de) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'e>(1,4>diazepin-6-one und -thione und ihre verwendung bei der aids-vorbeugung oder behandlung.
DE69209273D1 (de) Permselektive polyacrylnitrilcopolymermembran und ihre herstellung
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
NO306256B1 (no) Tricykliske 5,6-dihydro-9H-pyrazolo [3,4c]-1,2,4-triazolo [4,3-a]pyridiner, anvendelse derav og farmasöytisk preparat
CA2201723A1 (en) Colchicine derivatives and the therapeutical use thereof
ATE248821T1 (de) Neue 1,5- und 3-0-substituierte 1h-indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver wirkung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60001588D1 (de) Naphtopyrane mit einem perfluoroalkylsubstituenten in position 5, ihre herstellung, und diese enthaltende zusammensetzungen
NO20025461L (no) Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
DE59807020D1 (de) 1:2-chromkomplexfarbstoffe, deren herstellung und verwendung
ITTO950554A0 (it) Diamidi aromatiche acide ad attivita' antigastrinica, procedimento perla loro preparazione e loro uso farmaceutico
AU1929397A (en) Use of il-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties